Urogen Pharma (NASDAQ:URGN - Get Free Report) shares dropped 7.7% during mid-day trading on Tuesday . The stock traded as low as $13.15 and last traded at $13.24. Approximately 3,298,388 shares were traded during mid-day trading, an increase of 222% from the average daily volume of 1,024,297 shares. The stock had previously closed at $14.34.
Wall Street Analysts Forecast Growth
Several brokerages have recently weighed in on URGN. Scotiabank restated an "outperform" rating on shares of Urogen Pharma in a report on Friday, June 13th. D. Boral Capital reiterated a "buy" rating and set a $25.00 price target on shares of Urogen Pharma in a report on Thursday, June 12th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a "buy" rating in a report on Friday, June 13th. The Goldman Sachs Group set a $16.00 price target on shares of Urogen Pharma and gave the company a "neutral" rating in a research report on Friday, June 13th. Finally, HC Wainwright raised shares of Urogen Pharma from a "neutral" rating to a "buy" rating and set a $50.00 price target on the stock in a research report on Monday. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $32.86.
Check Out Our Latest Stock Report on URGN
Urogen Pharma Stock Down 1.5%
The firm's fifty day moving average price is $8.99 and its two-hundred day moving average price is $10.13. The stock has a market cap of $675.51 million, a price-to-earnings ratio of -4.61 and a beta of 0.40. The company has a debt-to-equity ratio of 4.77, a current ratio of 5.65 and a quick ratio of 5.47.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts' consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative return on equity of 97,487.15% and a negative net margin of 150.68%. Sell-side analysts forecast that Urogen Pharma will post -3.12 earnings per share for the current fiscal year.
Insider Buying and Selling at Urogen Pharma
In other Urogen Pharma news, insider Mark Schoenberg sold 5,162 shares of the stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider now owns 153,378 shares in the company, valued at approximately $1,130,395.86. This trade represents a 3.26% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 5.10% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the business. CWM LLC boosted its holdings in Urogen Pharma by 6,047.1% in the 1st quarter. CWM LLC now owns 5,225 shares of the company's stock valued at $58,000 after purchasing an additional 5,140 shares during the period. KLP Kapitalforvaltning AS purchased a new stake in shares of Urogen Pharma during the 4th quarter valued at $59,000. Lazard Asset Management LLC purchased a new stake in shares of Urogen Pharma during the 4th quarter valued at $67,000. GAMMA Investing LLC raised its position in shares of Urogen Pharma by 6,908.4% during the 1st quarter. GAMMA Investing LLC now owns 7,499 shares of the company's stock valued at $83,000 after buying an additional 7,392 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Urogen Pharma during the 4th quarter valued at $101,000. 91.29% of the stock is owned by institutional investors.
Urogen Pharma Company Profile
(
Get Free Report)
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.
Read More
Before you consider Urogen Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Urogen Pharma wasn't on the list.
While Urogen Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
